Press Room

News / Apr 12, 2021

Guy Villax wins EY Award “Entrepreneur of the Year”

EY Entrepreneur Of The Year is the world's most prestigious business award for entrepreneurs

Guy Villax Wins Entreperneur of the Year Award | Hovione

Guy Villax won the EY award "Entrepreneur of the Year" in Portugal and he will represent Portugal at the EY World "Entrepreneur of the Year", next June.

Upon receiving the award, Guy Villax stated that this is an important distinction for Hovione, above all it recognizes the team that built this company over the last 25 years, and he thanked and congratulated all Hovione Team Members for the success. Guy Villax also said that we are a company with 60+ years, with strong values, with innovation at its core, but to endure into the future it needs to be able to constantly re-invent itself: “A company that does not move forward, dies. You have to constantly look for opportunities, look for ways to stay ahead of the competition, and innovation is central to success”.
 
The EY Award "Entrepreneur Of The Year" was created in the USA in 1986 to recognize and encourage Entrepreneurs that are marked by creativity that invest themselves in a corporate project with vision and achieve success. In Portugal, the EY “Entrepreneur Of The Year” is in its 8th edition.

 

Votes are open for the election of EY World Entrepreneur Of The Year™ 2021:

Cast your vote here

 

 

 

 

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024